去腎交感神經術治療頑固性高血壓合并阻塞性睡眠呼吸暫停的研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

喻淑慧 , 李園園 ,  胡克

武漢大學人民醫院呼吸科(湖北武漢 430060);

Corresponding?author：

胡克, Email: hukejx@163.com

Keywords：

DOI：

10.7507/1671-6205.2015079

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 喻淑慧, 李園園, 胡克. 去腎交感神經術治療頑固性高血壓合并阻塞性睡眠呼吸暫停的研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2015, 14(3): 317-320. doi: 10.7507/1671-6205.2015079 Copy

1.	?Calhoun DA,Jones D,Textor S,et al. Resistant hypertension:diagnosis,evaluation,and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension,2008,51:1403-1419.
2.	中華醫學會呼吸病學分會睡眠呼吸疾病學組.阻塞性睡眠呼吸暫停低通氣綜合征診治指南(2011年修訂版).中華結核和呼吸雜志,2012,35:9-12.
3.	Witkowski A,Prejbisz A,Florczak E,et al. Effects of renal sympathetic denervation on blood pressure,sleep apnea course,and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension,2011,58:559-565.
4.	Peppard PE,Young T,Palta M,et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med,2000,342:1378-1384.
5.	中國醫師協會高血壓專業委員會,中華醫學會呼吸病學分會睡眠呼吸障礙學組.阻塞性睡眠呼吸暫停相關性高血壓臨床診斷和治療專家共識.中華高血壓雜志,2012,20:1119-1124.
6.	中華醫學會呼吸病學分會睡眠呼吸疾病學組.睡眠呼吸暫停人群高血壓患病率的多中心研究.中華結核和呼吸雜志,2007,30:894-897.
7.	Lloberes P,Lozano L,Sampol G,et al. Obstructive sleep apnoea and 24-h blood pressure in patients with resistant hypertension. J Sleep Res,2010,19:597-602.
8.	Bradley TD,Floras JS. Obstructive sleep apnoea and its cardiovascular consequences. Lancet,2009,373:82-93.
9.	涂學平,王念,胡克.慢性間歇缺氧引起高血壓的發病機制.中國呼吸與危重監護雜志,2012,11:513-516.
10.	Gjorup PH,Sadauskiene L,Wessels J,et al. Abnormally increased endothelin-1 in plasma during the night in obstructive sleep apnea:relation to blood pressure and severity of disease. Am J Hypertens,2007,20:44-52.
11.	Clark DR,Ahmed MI,Calhoun DA. Resistant hypertension and aldosterone:an update. Can J Cardiol,2012,28:318-325.
12.	Mcnicholas WT. Chronic obstructive pulmonary disease and obstructive sleep apnea:overlaps in pathophysiology,systemic inflammation,and cardiovascular disease. Am J Respir Crit Care Med,2009,180:692-700.
13.	Schmieder RE,Redon J,Grassi G,et al. ESH position paper:renal denervation-an interventional therapy of resistant hypertension. J Hypertens,2012,30:837-841.
14.	Krum H,Schlaich M,Whitbourn R,et al. Catheter-based renal sympathetic denervation for resistant hypertension:a multicentre safety and proof-of-principle cohort study. Lancet,2009,373:1275-1281.
15.	Esler MD,Krum H,Sobotka PA,et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial):a randomised controlled trial. Lancet,2010,376:1903-1909.
16.	Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension:durability of blood pressure reduction out to 24 months. Hypertension,2011,57:911-917.
17.	Krum H,Schlaich MP,Sobotka PA,et al. Percutaneous renal denervation in patients with treatment-resistant hypertension:final 3-year report of the Symplicity HTN-1 study. Lancet,2014,383:622-629.
18.	Esler MD,Bohm M,Sievert H,et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension:36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J,2014,35:1752-1759.
19.	Bhatt DL,Kandzari DE,O’Neill WW,et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med,2014,370:1393-1401.
20.	B?hm M. Medtronic Global SYMPLICITY Registry Shows Strong Safety Profile of the Symplicity(TM) Renal Denervation System. Six-Month Analysis of First 1,000 Patients Enrolled in Real-World Patient Registry;Proceedings of American College of Cardiology 2014 scientific sessions. Washington:cardio source,DC,USA,2014:29-31.
21.	Shantha GP,Pancholy SB. Effect of renal sympathetic denervation on apnea-hypopnea index in patients with obstructive sleep apnea:a systematic review and meta-analysis. Sleep Breath,2015,19:29-34.
22.	趙蒙蒙,譚雪雪,丁寧,等.腎動脈去交感神經射頻消融與持續氣道正壓通氣對高血壓合并阻塞性睡眠呼吸暫停綜合征的療效比較.中華醫學雜志,2013,93:1234-1237.
23.	Yumino D,Redolfi S,Ruttanaumpawan P,et al. Nocturnal rostral fluid shift:a unifying concept for the pathogenesis of obstructive and central sleep apnea in men with heart failure. Circulation,2010,121:1598-1605.
24.	Gaddam K,Pimenta E,Thomas SJ,et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension:a preliminary report. J Hum Hypertens,2010,24:532-537.
25.	Koistinen HA,Zierath JR. Regulation of glucose transport in human skeletal muscle. Ann Med,2002,34:410-418.
26.	Kjeldsen SE,Narkiewicz K,Oparil S,et al. Blood pressure lowering effect of renal sympathetic denervation or placebo?-building expectations for Symplicity-HTN 3. Blood Press,2013,22:279-281.
27.	Persu A,Jin Y,Fadl EF,et al. Renal denervation after Symplicity HTN-3:an update. Curr Hypertens Rep,2014,16:460.

1. ?Calhoun DA,Jones D,Textor S,et al. Resistant hypertension:diagnosis,evaluation,and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension,2008,51:1403-1419.
2. 中華醫學會呼吸病學分會睡眠呼吸疾病學組.阻塞性睡眠呼吸暫停低通氣綜合征診治指南(2011年修訂版).中華結核和呼吸雜志,2012,35:9-12.
3. Witkowski A,Prejbisz A,Florczak E,et al. Effects of renal sympathetic denervation on blood pressure,sleep apnea course,and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension,2011,58:559-565.
4. Peppard PE,Young T,Palta M,et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med,2000,342:1378-1384.
5. 中國醫師協會高血壓專業委員會,中華醫學會呼吸病學分會睡眠呼吸障礙學組.阻塞性睡眠呼吸暫停相關性高血壓臨床診斷和治療專家共識.中華高血壓雜志,2012,20:1119-1124.
6. 中華醫學會呼吸病學分會睡眠呼吸疾病學組.睡眠呼吸暫停人群高血壓患病率的多中心研究.中華結核和呼吸雜志,2007,30:894-897.
7. Lloberes P,Lozano L,Sampol G,et al. Obstructive sleep apnoea and 24-h blood pressure in patients with resistant hypertension. J Sleep Res,2010,19:597-602.
8. Bradley TD,Floras JS. Obstructive sleep apnoea and its cardiovascular consequences. Lancet,2009,373:82-93.
9. 涂學平,王念,胡克.慢性間歇缺氧引起高血壓的發病機制.中國呼吸與危重監護雜志,2012,11:513-516.
10. Gjorup PH,Sadauskiene L,Wessels J,et al. Abnormally increased endothelin-1 in plasma during the night in obstructive sleep apnea:relation to blood pressure and severity of disease. Am J Hypertens,2007,20:44-52.
11. Clark DR,Ahmed MI,Calhoun DA. Resistant hypertension and aldosterone:an update. Can J Cardiol,2012,28:318-325.
12. Mcnicholas WT. Chronic obstructive pulmonary disease and obstructive sleep apnea:overlaps in pathophysiology,systemic inflammation,and cardiovascular disease. Am J Respir Crit Care Med,2009,180:692-700.
13. Schmieder RE,Redon J,Grassi G,et al. ESH position paper:renal denervation-an interventional therapy of resistant hypertension. J Hypertens,2012,30:837-841.
14. Krum H,Schlaich M,Whitbourn R,et al. Catheter-based renal sympathetic denervation for resistant hypertension:a multicentre safety and proof-of-principle cohort study. Lancet,2009,373:1275-1281.
15. Esler MD,Krum H,Sobotka PA,et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial):a randomised controlled trial. Lancet,2010,376:1903-1909.
16. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension:durability of blood pressure reduction out to 24 months. Hypertension,2011,57:911-917.
17. Krum H,Schlaich MP,Sobotka PA,et al. Percutaneous renal denervation in patients with treatment-resistant hypertension:final 3-year report of the Symplicity HTN-1 study. Lancet,2014,383:622-629.
18. Esler MD,Bohm M,Sievert H,et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension:36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J,2014,35:1752-1759.
19. Bhatt DL,Kandzari DE,O’Neill WW,et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med,2014,370:1393-1401.
20. B?hm M. Medtronic Global SYMPLICITY Registry Shows Strong Safety Profile of the Symplicity(TM) Renal Denervation System. Six-Month Analysis of First 1,000 Patients Enrolled in Real-World Patient Registry;Proceedings of American College of Cardiology 2014 scientific sessions. Washington:cardio source,DC,USA,2014:29-31.
21. Shantha GP,Pancholy SB. Effect of renal sympathetic denervation on apnea-hypopnea index in patients with obstructive sleep apnea:a systematic review and meta-analysis. Sleep Breath,2015,19:29-34.
22. 趙蒙蒙,譚雪雪,丁寧,等.腎動脈去交感神經射頻消融與持續氣道正壓通氣對高血壓合并阻塞性睡眠呼吸暫停綜合征的療效比較.中華醫學雜志,2013,93:1234-1237.
23. Yumino D,Redolfi S,Ruttanaumpawan P,et al. Nocturnal rostral fluid shift:a unifying concept for the pathogenesis of obstructive and central sleep apnea in men with heart failure. Circulation,2010,121:1598-1605.
24. Gaddam K,Pimenta E,Thomas SJ,et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension:a preliminary report. J Hum Hypertens,2010,24:532-537.
25. Koistinen HA,Zierath JR. Regulation of glucose transport in human skeletal muscle. Ann Med,2002,34:410-418.
26. Kjeldsen SE,Narkiewicz K,Oparil S,et al. Blood pressure lowering effect of renal sympathetic denervation or placebo?-building expectations for Symplicity-HTN 3. Blood Press,2013,22:279-281.
27. Persu A,Jin Y,Fadl EF,et al. Renal denervation after Symplicity HTN-3:an update. Curr Hypertens Rep,2014,16:460.

Previous Article
急性嗜酸粒細胞性肺炎的研究進展
Next Article
特發性肺泡蛋白沉積癥治療進展

Chinese Journal of Respiratory and Critical Care Medicine

去腎交感神經術治療頑固性高血壓合并阻塞性睡眠呼吸暫停的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content